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Advances in technology, including new imaging modalities,
genomic tests, and biomarkers, have introduced practicechanging opportunities for the treatment of localized prostate
cancer. These advances will allow us to better determine
which patients are appropriate candidates for active surveillance and when to offer patients curative treatment. With
the rising use of MRI-guided biopsy, further questions about
when, and on whom, to use MRI-guided biopsy have been
raised. In a quest to highlight best practices for achieving
best cancer detection rates for patients with previous negative
biopsies, C.-H. Chang et al. compared the prostate cancer
detection rates of targeted biopsy and saturation biopsy in
patients with previous negative biopsy and the accuracy of
these biopsies retrospectively stratified by different serum
prostate-specific antigen (PSA) levels. Of the 185 patients
enrolled in the study, they found that combining target biopsy
(TB) and saturation biopsy (SB) achieved the best cancer
detection rate. Furthermore, the accuracy of TB was better
than that of SB in patients with serum PSA > 10 ng/mL.
More work is needed to evaluate different biopsy strategies
in patients with varying PSA levels. Using a recently released
robot guided, software based transperineal approach, M.
Kroenig et al. compared prostate cancer detection rates
between MRI-TRUS fusion targeted and systematic biopsies.
52 patients with elevated PSA levels, clinical suspicion for
prostate cancer, and prior negative 12-core transrectal ultrasound guided biopsy received MRI/TRUST fusion biopsy at
the University of Freiburg Medical Centre. This group was
unable to exhibit an advantage in the overall detection rate
of clinically significant prostate cancer using the MRI/TRUS

fusion biopsy. This study highlights the potential to improve
the radiological PI-RADSv2 classification scheme in order to
reduce sensitivity issues.
Is it safe to offer young patients active surveillance?
What are the long-term side-effects of treatment that young
men might face? In this special issue, D. Milonas et al.
report long-term outcomes of young men treated with radical
prostatectomy. They compared long-term outcomes of 277
men aged ≤55 years after radical prostatectomy (RP) with an
older cohort. Pathological tumor characteristics, biochemical
recurrence rates (BCR), and disease progression rates were
compared between the two groups. This group found that the
younger cohort had superior outcomes especially when their
Gleason score, lymph-nodes, and surgical margins status
were lower, and the two cohorts had similar BCR. This study
highlights the excellent results that RP has for younger men
(≤55 years) with localized prostate cancer.
Treatment advances will also aid in a personalized
approach to treatment, giving patients more information
about their cancer and expected cancer and side-effects of
any given treatment. E. Reamer et al. discuss the role of social
support and personality differences in men when it comes to
prostate cancer treatment selection. In their report, E. Reamer
et al. analyzed social influences on the treatment decisionmaking process of 559 men ≤ 75 years old newly diagnosed
with localized prostate cancer. A population-based sample
was surveyed cross-sectionally from Detroit, Michigan, and
cases were identified by the Metropolitan Detroit Cancer
Surveillance System (MDCSS). They evaluated treatment
choice, reason for the choice, decision-making difficulty,
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satisfaction, and regret. They found that, in addition to seeing
a specialist, consulting friends increased men’s likelihood
of choosing curative treatment and that consulting family or friends increased decision-making difficulty. With a
racially diverse cohort, this study highlights the importance
of social networks during a patient’s treatment decisionmaking process, and it has implications for how physicians
should develop realistic expectations of treatments across
communities.
And in an effort to increase awareness about the developments in definitive radiotherapy and compare its outcomes to
radical prostatectomy, B. G. L. Vanneste et al. wrote a narrative review on a number of publications regarding definitive
treatments for prostate cancer. The current literature did not
reveal significant difference between conventional, definitive
treatment modalities in cure rates, but in toxicity patterns.
The paper focuses its conclusions on patient-specific treatment and recommending different treatment types based on
their own advantages and side-effects in correspondence to
the specific needs and concerns of individual patients.
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